A phase 1 trial of Allogene's of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA, after a "chromosomal abnormality" was seen in a patient receiving the cell therapy.
In 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the CAR-T cancer cell therapies they had just sold to Gilead for $12 billion with an "off-the
Century Therapeutics has emerged from stealth mode to develop a new generation of ‘off the shelf’ cancer cell therapies, with $250 million backing from investors including Bayer.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh